UroGen Pharma Ltd. (URGN)
- Previous Close
14.53 - Open
14.66 - Bid 14.19 x 300
- Ask 14.28 x 200
- Day's Range
14.19 - 14.76 - 52 Week Range
8.69 - 24.13 - Volume
91,852 - Avg. Volume
372,220 - Market Cap (intraday)
484.875M - Beta (5Y Monthly) 1.08
- PE Ratio (TTM)
-- - EPS (TTM)
-3.55 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
38.50
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
www.urogen.comRecent News: URGN
Performance Overview: URGN
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: URGN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: URGN
Valuation Measures
Market Cap
484.87M
Enterprise Value
447.30M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.95
Price/Book (mrq)
--
Enterprise Value/Revenue
5.41
Enterprise Value/EBITDA
-5.46
Financial Highlights
Profitability and Income Statement
Profit Margin
-123.61%
Return on Assets (ttm)
-26.09%
Return on Equity (ttm)
--
Revenue (ttm)
82.71M
Net Income Avi to Common (ttm)
-102.24M
Diluted EPS (ttm)
-3.55
Balance Sheet and Cash Flow
Total Cash (mrq)
136.97M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-34.14M